Medical Patent Law Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

MedImmune

Reports from MedImmune highlight the latest developments

This trend article is an immediate alert from NewsRx to identify the most recent news developments at MedImmune.

Report 1: MedImmune, Inc. (MEDI) announced that it intends to develop a monoclonal antibody (MAb) targeting pathways within the CD28 receptor family for treatment of certain inflammatory diseases under a recently signed license agreement with Japan Tobacco, Inc. (JT).

MedImmune's initial efforts will focus on developing the current lead antibody, which aims to inhibit a receptor believed to play a key role in controlling adaptive immune responses, called...

• View Other Issues of Medical Patent Law Weekly
  
• View Other NewsRx Publications